Shane Crotty

Dec 17, 2024 | nature.com | Shane Crotty

Correction to: Nature https://doi.org/10.1038/s41586-024-07748-8 Published online 31 July 2024In the version of the article initially published, in the bottom row of Extended Data Fig. 4b, the third and fourth plots were duplicates of the second. The figure has been amended in the HTML and PDF versions of the article. About this articleRamirez, S.I., Faraji, F., Hills, L.B. et al. Author Correction: Immunological memory diversity in the human upper airway. Nature (2024).

Nov 28, 2024 | cell.com | Caterina E. Faliti |Jinyong Choi |Simon Belanger |Christopher M. Tipton |Sakeenah L. Hicks |Maria Cardenas | +17 more

KeywordsantibodiesvaccineCD4 T cellsT follicular helper cellsTfh cellsplasma cellsIL-2 cytokinemTORmetabolismGet full text accessLog in, subscribe or purchase for full access. References1. Radbruch, A. ∙ Muehlinghaus, G. ∙ Luger, E.O. ... Competence and competition: the challenge of becoming a long-lived plasma cellNat. Rev. Immunol. 2006; 6:741-7502. Slifka, M.K. ∙ Antia, R. ∙ Whitmire, J.K. ... Humoral immunity due to long-lived plasma cellsImmunity. 1998; 8:363-3723.

Jun 14, 2024 | nature.com | Ivy Phung |Olivia K. Swanson |Chang-Chun D. Lee |Ester Marina-Zárate |Gabriel Ozorowski |Kimmo Rantalainen | +28 more

Correction to: Nature Immunology https://doi.org/10.1038/s41590-024-01833-w, published online 30 May 2024In the version of the article initially published, Steven Schultze’s surname appeared incorrectly (as Schulze) and has now been amended in the HTML and PDF versions of the article.

May 30, 2024 | nature.com | Ivy Phung |Olivia K. Swanson |Chang-Chun D. Lee |Ester Marina-Zárate |Gabriel Ozorowski |Kimmo Rantalainen | +28 more

AbstractA key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of priming immunogens that induce rare bnAb-precursor B cells.

Mar 28, 2023 | newswise.com | Shane Crotty |Erica Ollmann Saphire

There are no vaccines or therapies available for lymphocytic choriomeningitis virus (LCMV) infection. This pathogen spreads easily and is extremely common in people worldwide. Infection with LCMV can cause birth defects in developing fetuses, and severe illness and even death in the immuncompromised. New findings from La Jolla Institute for Immunology (LJI) scientists show how an engineered antibody can target LCMV and neutralize the virus.